Inovio Pharmaceuticals Statistics

Total Valuation

Inovio Pharmaceuticals has a market cap or net worth of GBP 60.70 million. The enterprise value is 2.49 million.

Market Cap	60.70M
Enterprise Value	2.49M

Important Dates

The next estimated earnings date is Friday, February 28, 2025.

Earnings Date	Feb 28, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+16.75%
Shares Change (QoQ)	+3.47%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	35.68M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	1.11
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-0.03
EV / Sales	15.19
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-0.03

Financial Position

The company has a current ratio of 3.88, with a Debt / Equity ratio of 0.17.

Current Ratio	3.88
Quick Ratio	3.69
Debt / Equity	0.17
Debt / EBITDA	n/a
Debt / FCF	-0.11
Interest Coverage	-263.84

Financial Efficiency

Return on equity (ROE) is -106.64% and return on invested capital (ROIC) is -59.76%.

Return on Equity (ROE)	-106.64%
Return on Assets (ROA)	-50.56%
Return on Invested Capital (ROIC)	-59.76%
Return on Capital Employed (ROCE)	-145.29%
Revenue Per Employee	1,195
Profits Per Employee	-663,125
Employee Count	122
Asset Turnover	0.00
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -64.84% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-64.84%
50-Day Moving Average	2.76
200-Day Moving Average	6.94
Relative Strength Index (RSI)	41.84
Average Volume (20 Days)	27,376

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	4.83

Income Statement

In the last 12 months, Inovio Pharmaceuticals had revenue of GBP 151,766 and -84.22 million in losses. Loss per share was -3.32.

Revenue	151,766
Gross Profit	-61.01M
Operating Income	-90.58M
Pretax Income	-84.22M
Net Income	-84.22M
EBITDA	-89.16M
EBIT	-90.58M
Loss Per Share	-3.32

Full Income Statement

Balance Sheet

The company has 63.27 million in cash and 9.29 million in debt, giving a net cash position of 53.99 million.

Cash & Cash Equivalents	63.27M
Total Debt	9.29M
Net Cash	53.99M
Net Cash Per Share	n/a
Equity (Book Value)	54.87M
Book Value Per Share	2.11
Working Capital	50.57M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -82.58 million and capital expenditures -363,971, giving a free cash flow of -82.95 million.

Operating Cash Flow	-82.58M
Capital Expenditures	-363,971
Free Cash Flow	-82.95M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-59,685.42%
Pretax Margin	-55,491.25%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Inovio Pharmaceuticals does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-16.75%
Shareholder Yield	-16.75%
Earnings Yield	-138.74%
FCF Yield	-136.65%

Stock Splits

The last stock split was on January 25, 2024. It was a reverse split with a ratio of 0.0833333333.

Last Split Date	Jan 25, 2024
Split Type	Reverse
Split Ratio	0.0833333333

Scores

Inovio Pharmaceuticals has an Altman Z-Score of -21.81. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-21.81
Piotroski F-Score	n/a